Top 5 Initiations:

Top 5 Initiations:


 Nicole Fischer, an employee of US battery manufacturer Microvast, sets down a battery module during the end-of-line test. (Photo by Soeren Stache/picture alliance via Getty Images)



Needham initiated coverage of MoonLake Immunotherapeutics (MLTX) with a Buy rating and $76 price target. The company's sonelokimab, a dual IL-17A/-17F inhibitor nanobody for various chronic dermatology conditions, has demonstrated "best-in-class potential" in hidradenitis suppurativa and psoriasis with superior efficacy versus well known biologics, the firm tells investors in a research note.


Janney Montgomery Scott initiated coverage of Microvast (MVST) with a Buy rating and $8 fair value estimate. which represents 400% upside. The firm thinks the company's transition over the next 12 months out of capacity expansion into revenue harvesting, supported by a $676M backlog, will drive an improved stock price.

Comments

Post a Comment

Popular posts from this blog

How can both fund managers and wealth managers

 How can both fund managers and wealth managers  expand investor acquisition through digital marketing without access to data from cookies? The keys are highly focused data, targeted media and streamlined compliance, which are all well within reach with today’s technology. Astute data-driven firms are building proprietary databases. My firm started the process immediately once we saw the impact that new privacy laws would likely have on the soon-to-be “old” digital advertising. Millions of accredited and near-accredited individuals are sorted into targeted lists by behavioral  categories, including C-suite executives at small and midsize companies, Ph.D. holders, MBAs, doctors, dentists, attorneys and accountants , and some with really intriguing attributes. including recent retirees.
Read more